ARIMOCLOMOL: PIPELINE-IN-A-PRODUCT POTENTIAL

Scroll over the pipeline chart to read more about each disease area.

DESIGNATIONS
STAGE OF DEVELOPMENT
ANTICIPATED MILESTONES
Orphan Drug
Fast Track
BTD**
PC
Ph1
Ph2
Ph3
Filed
Anticipated Milestones
Niemann-Pick disease type C*

DESIGNATIONS

Orphan Drug
Fast Track
BTD**
Orpha Drug
Orpha Drug
Orpha Drug
STAGE OF DEVELOPMENT
PC
Ph1
Ph2
Ph3
Filed
Ph 2/3 (data reported)
ANTICIPATED MILESTONES

U.S. FDA accepted New Drug Application (NDA) for review; Submitted MAA (EU) 2020

Niemann-Pick disease type C (NPC) is a rare progressive neurodegenerative disease. It belongs to the family of lysosomal storage diseases. Niemann-Pick disease type C can be difficult to recognize, which leads to diagnostic delays. There are no approved treatments in the United States for Niemann-Pick disease type C.
Gaucher disease***

DESIGNATIONS

None

Orphan Drug
Fast Track
BTD**
STAGE OF DEVELOPMENT
PC
Ph1
Ph2
Ph3
Filed
Ph 2 (top-line
data reported)
ANTICIPATED MILESTONES

Gaucher disease is a rare, inherited lysosomal storage disorder causing certain sugar-containing fats to abnormally accumulate in the lysosomes of cells, especially within cells of the blood system and nerve cells, thereby affecting organs such as the brain, bone marrow, spleen, and liver. The typical systemic symptoms of Gaucher disease, which can appear at any age, include an abnormally enlarged liver and/or spleen and low levels of circulating red blood cells and platelets. Currently no treatments are available that can cross the blood brain barrier to help reduce neurological symptoms.
*Early-access program is underway at multiple sites; **Breakthrough Therapy Designation (BTD);
***Type 1 and Type 3 Gaucher disease;
Rare pediatric disease designation.